Otezla (Apremilast)

Otezla (Apremilast) Medication Information

Uses

Otezla is a phosphodiesterase inhibitor that is used to treat plaque psoriasis and psoriatic arthritis. 

Dosage

The tablets come in several different strengths:

• 10 mg
• 20 mg
• 30 mg

Side Effects

The most common side effects of Otezla include:

• Diarrhea
• Nausea
• headache

Speak with your doctor for a full list of side effects that apply to you if you are taking Apremilast.

Precautions

There is a risk of depression while taking Otezla, patients should be monitored for changes in behavior while taking Otezla. 

There is a risk of weight decreases while taking Otezla, weight should be monitored regularly during treatment. 

Interactions

The most common drug interactions with Otezla include:

• Ketoconazole
• Rifampin
• Phenobarbital
• Carbamazepine
• Phenytoin 

Speak with your doctor for more information and before starting a new medication with Apremilast. 

Storage

Store below room temperature (86 ºF). 

Pharmacist Tips

• Otezla can cause diarrhea and vomiting, if this becomes severe you should seek medical attention.
• Apremilast can cause weight loss, so it is important to monitor your weight regularly. 
• To reduce stomach upset Otezla should be slowly titrated. 

Apremilast FAQs

What does Otezla do?

Otezla reduces the phosphodiesterase activity in cells which can reduce overactive inflammation in patients with psoriasis. 

Does Otezla reduce inflammation?

Yes, Apremilast reduces inflammation in patients with psoriasis. 

How long can you be on Otezla?

Otezla is a long term treatment and you should stay on it until your doctor says otherwise.

Can you take Otezla on an empty stomach?

Yes, you can take Otezla with or without food.

Does Otezla cure psoriasis?

No, Apremilast will not cure psoriasis, it will return of the medication is stopped.

Related Drugs

• Enstilar
• Humira
• Taclonex Gel
• Temovate Ointment

Reference:

Otezla {package insert}. Summit, NJ: Celegene Corporation 2017.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205437s006lbl.pdf